Bhat-Nakshatri Poornima, Wang Guohua, Collins Nikail R, Thomson Michael J, Geistlinger Tim R, Carroll Jason S, Brown Myles, Hammond Scott, Srour Edward F, Liu Yunlong, Nakshatri Harikrishna
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Nucleic Acids Res. 2009 Aug;37(14):4850-61. doi: 10.1093/nar/gkp500. Epub 2009 Jun 14.
Estradiol (E2) regulates gene expression at the transcriptional level by functioning as a ligand for estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). E2-inducible proteins c-Myc and E2Fs are required for optimal ERalpha activity and secondary estrogen responses, respectively. We show that E2 induces 21 microRNAs and represses seven microRNAs in MCF-7 breast cancer cells; these microRNAs have the potential to control 420 E2-regulated and 757 non-E2-regulated mRNAs at the post-transcriptional level. The serine/threonine kinase, AKT, alters E2-regulated expression of microRNAs. E2 induced the expression of eight Let-7 family members, miR-98 and miR-21 microRNAs; these microRNAs reduced the levels of c-Myc and E2F2 proteins. Dicer, a ribonuclease III enzyme required for microRNA processing, is also an E2-inducible gene. Several E2-regulated microRNA genes are associated with ERalpha-binding sites or located in the intragenic region of estrogen-regulated genes. We propose that the clinical course of ERalpha-positive breast cancers is dependent on the balance between E2-regulated tumor-suppressor microRNAs and oncogenic microRNAs. Additionally, our studies reveal a negative-regulatory loop controlling E2 response through microRNAs as well as differences in E2-induced transcriptome and proteome.
雌二醇(E2)作为雌激素受体α(ERα)和雌激素受体β(ERβ)的配体,在转录水平调节基因表达。E2诱导的蛋白c-Myc和E2Fs分别是最佳ERα活性和继发性雌激素反应所必需的。我们发现E2在MCF-7乳腺癌细胞中诱导21种微小RNA并抑制7种微小RNA;这些微小RNA有可能在转录后水平控制420种E2调节的和757种非E2调节的mRNA。丝氨酸/苏氨酸激酶AKT可改变E2调节的微小RNA表达。E2诱导了8种Let-7家族成员、miR-98和miR-21微小RNA的表达;这些微小RNA降低了c-Myc和E2F2蛋白的水平。Dicer是微小RNA加工所需的核糖核酸酶III,也是一种E2诱导基因。几个E2调节的微小RNA基因与ERα结合位点相关或位于雌激素调节基因的基因内区域。我们提出,ERα阳性乳腺癌的临床进程取决于E2调节的肿瘤抑制微小RNA和致癌微小RNA之间的平衡。此外,我们的研究揭示了一个通过微小RNA控制E2反应的负调控环以及E2诱导的转录组和蛋白质组的差异。